Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

[1]  V. Haddad,et al.  Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Gascón,et al.  Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy , 2008, Clinical Cancer Research.

[4]  K. Fizazi,et al.  The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. Saad,et al.  Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. , 2007, Urology.

[6]  A. Jimeno,et al.  Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists , 2006, Clinical Cancer Research.

[7]  J. Body,et al.  A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[10]  T. Sone,et al.  Analysis of three-dimensional microarchitecture and degree of mineralization in bone metastases from prostate cancer using synchrotron microcomputed tomography. , 2004, Bone.

[11]  R. Coleman,et al.  Bone resorption predicts for skeletal complications in metastatic bone disease , 2003, British Journal of Cancer.

[12]  C. Logothetis,et al.  Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. Wood,et al.  Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. , 2001, Cancer research.

[14]  P. Kostenuik,et al.  The effects of osteoprotegerin on the mechanical properties of rat bone , 2001, Journal of materials science. Materials in medicine.

[15]  D L Lacey,et al.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.

[16]  J. Pfeilschifter,et al.  Osteoporosis due to cancer treatment: pathogenesis and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  David B. Burr,et al.  Skeletal Tissue Mechanics , 1998, Springer New York.

[18]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[19]  N. Clarke,et al.  Morphometric evidence for bone resorption and replacement in prostate cancer. , 1991, British journal of urology.

[20]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.